Adopting cell membrane vesicles derived from bone marrow MSCs overexpressing CXCR4 to target bone marrow. Subsequently, target AML cells through CD33 and CD123 aptamers anchored on the vesicles. Here, CD33 is linked to acute myeloid leukemia.